Ambit logo

Ambit

Driving breakthroughs in cancer and inflammatory disease treatment through pioneering kinase inhibitor research and innovative clinical collaborations.

197 employees · est. 2000

VS
Deciphera Pharmaceuticals logo

Deciphera Pharmaceuticals

A member of ONO Group

526 employees · est. 2003 · Waltham, United States

Ambit is the older company (2000 vs 2003); Deciphera Pharmaceuticals is the larger of the two.

Side-by-Side Comparison

Ambit Deciphera Pharmaceuticals
Founded
2000 older 2003
Headquarters
Not tracked yet Waltham, United States
Employees
197 526 larger
Industry
Biopharma, Biotechnology, Health Care Not tracked yet
Funding Stage
Series Unknown Acquired
Total Funding
$215.73M $3.54B
Funding Rounds
10 10
Services
Not tracked yet Design and Development of Kinase Inhibitors, Clinical Trials and Studies, Expanded Access Program, Patient Response Improvement Programs
Target Customers
Not tracked yet Patients with Cancer, Healthcare Professionals, Pharmaceutical Partners, Clinical Researchers
Taxonomy
Biopharmaceutical, Kinase Inhibitors, Cancer Treatment, Inflammatory Disease, Clinical Trials, FLT3 Inhibitor, Oncology, Astellas Pharma Inc., Small Molecule Drugs, AC220, AC480, AC430, JAK2 Inhibitor, Preclinical Pipeline, Drug Discovery Biopharmaceutical, Cancer Treatment, Medicines Development, Switch-control Kinase Inhibitors, Kinase Biology, Drug Discovery, Oncology, Innovation In Medicine, Pharmaceutical Research, Tumor Treatment, Biotech Innovation, Kinase Inhibitor Platform
Website
ambitbio.com deciphera.com
Ambit logo

About Ambit

Ambit Biosciences is a biopharmaceutical company founded in 2000 with a focus on discovering and developing small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other conditions. The company's lead compound, AC220, is a highly selective FMS-like tyrosine kinase-3 (...

Deciphera Pharmaceuticals logo

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, under the slogan A member of ONO Group, is a noteworthy player in the biopharmaceutical sector, dedicated to innovating crucial cancer treatments. Established in 2003, the company leverages a proprietary switch-control kinase inhibitor platform that capitalizes on extensiv...

We will tell you when either one moves

BounceWatch watches Ambit and Deciphera Pharmaceuticals for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Ambit and Deciphera Pharmaceutic... — by email.

Frequently Asked Questions

Ambit — Driving breakthroughs in cancer and inflammatory disease treatment through pioneering kinase inhibitor research and innovative clinical collaborations.. Deciphera Pharmaceuticals — A member of ONO Group. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Ambit has raised $215.73M while Deciphera Pharmaceuticals has raised $3.54B.
Ambit and Deciphera Pharmaceuticals operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Ambit with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Ambit on 12 Sep 2024, and Deciphera Pharmaceuticals on 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy